Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892060899> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2892060899 endingPage "6095" @default.
- W2892060899 startingPage "6095" @default.
- W2892060899 abstract "6095 Background: Salivary gland cancers (SGC) are rare, biologically and histologically diverse malignancies with no standard of care therapy in the recurrent/metastatic setting. Eribulin is a microtubule inhibitor with established efficacy in previously treated breast cancer. The purpose of this study was to determine the anticancer activity of eribulin in advanced SGC. Methods: In a single center two-stage single arm phase II design, patients with progressive, recurrent and/or metastatic SCG of the head and neck or other sites, with documented disease progression within the past 6 months and not amenable to curative intent therapy were eligible. Any number of prior cytotoxic chemotherapies was allowed. Patients received eribulin 1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicities. Response was assessed by CT imaging every 6 weeks. The primary endpoint was overall response rate by RECIST 1.1. Secondary endpoints were duration of response (DOR), progression free survival (PFS), disease control rate (DCR), and grade > = 3 toxicities. Results: Between May 2012 and August 2015, 29 patients were enrolled. Median age was 63 (range 34-75); 20 (69%) were male. The most common histologies were adenoid cystic (n = 10) and adenocarcinoma (n = 5). Prior radiation was administered in 25 (86%). Number of prior cytotoxic therapies were: 0 (12, 41%), 1 (13, 45%), 3(3, 10%), 5 (1, 3%). Neutropenia was the most common toxicity (Grade 3 (9, 31%), Grade 4 (4, 14%)). Other grade 3 toxicities were: febrile neutropenia, increased QTc, fatigue and peripheral neuropathy in a single patient each. Median follow-up is 2 years, with 5 patients continuing on treatment. The median number of cycles administered was 4 (range 2-28). Response by RECIST criteria was observed in 3/29 (10%) with 2 PR and 1 CR , 20/29 (69%) patients demonstrated a decrement in tumor size at first assessment. Median PFS was 3 months, DCR was 26/29 (90%) and median DOR was 17.2 months. Conclusions: In this phase II trial of eribulin for advanced SGC, we observed response rates similar to those reported to other cytotoxic therapies and superior to those observed in trials of TKIs. Toxicities were similar to those observed in prior trials with eribulin. Clinical trial information: NCT01613768." @default.
- W2892060899 created "2018-09-27" @default.
- W2892060899 creator A5034980758 @default.
- W2892060899 creator A5035169773 @default.
- W2892060899 creator A5058265665 @default.
- W2892060899 creator A5063427877 @default.
- W2892060899 creator A5070256948 @default.
- W2892060899 creator A5070493081 @default.
- W2892060899 creator A5086691720 @default.
- W2892060899 creator A5091168604 @default.
- W2892060899 date "2016-05-20" @default.
- W2892060899 modified "2023-10-18" @default.
- W2892060899 title "Phase II trial of eribulin for recurrent or metastatic salivary gland cancers." @default.
- W2892060899 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.6095" @default.
- W2892060899 hasPublicationYear "2016" @default.
- W2892060899 type Work @default.
- W2892060899 sameAs 2892060899 @default.
- W2892060899 citedByCount "2" @default.
- W2892060899 countsByYear W28920608992019 @default.
- W2892060899 countsByYear W28920608992021 @default.
- W2892060899 crossrefType "journal-article" @default.
- W2892060899 hasAuthorship W2892060899A5034980758 @default.
- W2892060899 hasAuthorship W2892060899A5035169773 @default.
- W2892060899 hasAuthorship W2892060899A5058265665 @default.
- W2892060899 hasAuthorship W2892060899A5063427877 @default.
- W2892060899 hasAuthorship W2892060899A5070256948 @default.
- W2892060899 hasAuthorship W2892060899A5070493081 @default.
- W2892060899 hasAuthorship W2892060899A5086691720 @default.
- W2892060899 hasAuthorship W2892060899A5091168604 @default.
- W2892060899 hasConcept C121608353 @default.
- W2892060899 hasConcept C126322002 @default.
- W2892060899 hasConcept C141071460 @default.
- W2892060899 hasConcept C143998085 @default.
- W2892060899 hasConcept C203092338 @default.
- W2892060899 hasConcept C2775930923 @default.
- W2892060899 hasConcept C2776387010 @default.
- W2892060899 hasConcept C2776694085 @default.
- W2892060899 hasConcept C2777063308 @default.
- W2892060899 hasConcept C2778039489 @default.
- W2892060899 hasConcept C2778850193 @default.
- W2892060899 hasConcept C509974204 @default.
- W2892060899 hasConcept C530470458 @default.
- W2892060899 hasConcept C535046627 @default.
- W2892060899 hasConcept C71924100 @default.
- W2892060899 hasConcept C90924648 @default.
- W2892060899 hasConceptScore W2892060899C121608353 @default.
- W2892060899 hasConceptScore W2892060899C126322002 @default.
- W2892060899 hasConceptScore W2892060899C141071460 @default.
- W2892060899 hasConceptScore W2892060899C143998085 @default.
- W2892060899 hasConceptScore W2892060899C203092338 @default.
- W2892060899 hasConceptScore W2892060899C2775930923 @default.
- W2892060899 hasConceptScore W2892060899C2776387010 @default.
- W2892060899 hasConceptScore W2892060899C2776694085 @default.
- W2892060899 hasConceptScore W2892060899C2777063308 @default.
- W2892060899 hasConceptScore W2892060899C2778039489 @default.
- W2892060899 hasConceptScore W2892060899C2778850193 @default.
- W2892060899 hasConceptScore W2892060899C509974204 @default.
- W2892060899 hasConceptScore W2892060899C530470458 @default.
- W2892060899 hasConceptScore W2892060899C535046627 @default.
- W2892060899 hasConceptScore W2892060899C71924100 @default.
- W2892060899 hasConceptScore W2892060899C90924648 @default.
- W2892060899 hasIssue "15_suppl" @default.
- W2892060899 hasLocation W28920608991 @default.
- W2892060899 hasOpenAccess W2892060899 @default.
- W2892060899 hasPrimaryLocation W28920608991 @default.
- W2892060899 hasRelatedWork W2071439457 @default.
- W2892060899 hasRelatedWork W2491703090 @default.
- W2892060899 hasRelatedWork W2571164384 @default.
- W2892060899 hasRelatedWork W2737124041 @default.
- W2892060899 hasRelatedWork W2767929921 @default.
- W2892060899 hasRelatedWork W2782589310 @default.
- W2892060899 hasRelatedWork W2794674313 @default.
- W2892060899 hasRelatedWork W2999712386 @default.
- W2892060899 hasRelatedWork W3087590574 @default.
- W2892060899 hasRelatedWork W3142135812 @default.
- W2892060899 hasVolume "34" @default.
- W2892060899 isParatext "false" @default.
- W2892060899 isRetracted "false" @default.
- W2892060899 magId "2892060899" @default.
- W2892060899 workType "article" @default.